Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
DVLOP, a network of expert partners in preclinical and clinical development
Home . Service . DVLOP: partners in preclinical and clinical development
Complementary expertise for successful progress at each stage of your development
After the discovery and proof-of-concept phases, the preclinical development of new therapeutic entities is a critical step for the regulatory approval of the first-in-man administration and the transition to the early phases of clinical trials. DVLOP, a network of expert partners all renowned and experienced in preclinical and clinical development, is the solution to successfully complete this phase. Together with our partners Cynbiose, ERBC and PharmaLexwe bring you advice and support to define and implement your pre-clinical and clinical strategic program in line with your requirements and those of the regulatory authorities.
Oncodesign: From target to the IND for new targeted and innovative therapies
Cynbiose: Exploratory studies in pharmacology, safety and proof of concept using translational models in non-human primates
ERBC: Regulatory preclinical safety and toxicity studies
PharmaLex: Clinical development, pharmacovigilance and regulatory affairs
DVLOP addresses all the needs of start-ups, small and medium biotechnology companies that need expertise in the preclinical and clinical phases of drug development, but also large pharmaceutical companies with specialized development needs.